|
| Thursday, 30 September 2021, 16:00 HKT/SGT | |
| |  | |
Source: A*STAR | |
|
|
|
|
| - System supports Pfizer-BioNTech COVID-19 Vaccine, could support Moderna Vaccine as well |
SINGAPORE, Sept 30, 2021 - (ACN Newswire) - The Agency for Science, Technology and Research (A*STAR) has developed an Automated Vaccine Inoculation Dispenser (AVID) system, which replaces the manual step of filling injection syringes with vaccine liquid. AVID is customised for vaccination centres set up by the Ministry of Health and operated by private healthcare providers.
 | | Automated Vaccine Inoculation Dispenser (AVID) developed by A*STAR's Advanced Remanufacturing and Technology Centre (ARTC) and Singapore Institute of Manufacturing Technology (SIMTech) in collaboration with local systems integrator Sysmatic Global. |
AVID was designed to address the labour-intensive steps of the vaccination process to reduce the workload of healthcare providers, increase accuracy and productivity, and enhance personal safety as well. AVID currently supports the management of vials containing the Pfizer-BioNTech COVID-19 Vaccine, with potential to be customised for the Moderna Vaccine as well.
AVID was developed by researchers from A*STAR's Advanced Remanufacturing and Technology Centre (ARTC) and Singapore Institute of Manufacturing Technology (SIMTech), in collaboration with local systems integrator Sysmatic Global. The innovative HealthTech solution is the first of its kind to automate the extraction of vaccines from vials using a combination of robotic parts, smart sensors and digital technologies.
How it works:
- After thawing of the Pfizer-BioNTech COVID-19 Vaccine, it is diluted in the vial.
- Typically, healthcare providers would then have to extract individual doses of the vaccine (0.3 mL for the Pfizer-BioNTech COVID-19 Vaccine) using syringes. One vial of Pfizer-BioNTech COVID-19 vaccine contains six doses of vaccine after dilution(*).
- AVID automates this step of extraction of the vaccine from the vial into six individual syringes, including the dispersing of bubbles inside the syringes.
- AVID also automatically uncaps and recaps the syringes during the transfer of vaccine from vials to syringes.
- It is easy to use at just the push of some buttons, only needing simple training without any special qualifications required.
Benefits:
- Reduces workload of healthcare providers, by freeing them from the manual step of extracting vaccines from vials to syringes.
- Allows more focused attention by healthcare providers on interacting and communicating with people receiving the vaccinations.
- Increases productivity at vaccination centres via introduction of automated processes that are accurate, consistent, and fast.
- Reduces risks of cross-contamination and vaccine wastage via safe handling by the machine.
- Improves safety for healthcare providers by reducing the handling of sharp syringes during the extraction step.
- The machine's small footprint and low weight (less than 25kg) means it can be easily deployed to any vaccination centre.
Development and Deployment:
- AVID was developed within six weeks from conceptualisation. It is the result of a collaboration between A*STAR's ARTC and SIMTech, which provided expertise in robotics, automation and Industry 4.0 technologies, and Sysmatic Global, which designed, integrated and constructed the machine.
- AVID has been deployed in at least seven vaccination centres so far which administer the Pfizer-BioNTech COVID-19 Vaccine. Thomson Medical, a vaccination centre operator, also supported A*STAR in the development and trial of the machine.
(*) Health Sciences Authority, Singapore: fact sheet for healthcare providers administering Pfizer-BioNTech COVID-19 vaccine: https://bit.ly/3ikKZYt
** AVID fact sheet: www.acnnewswire.com/pdf/files/AVID_ASTAR_Sysmatic_FINAL.pdf
For media queries and clarifications, please contact:
Mr Robin Chan
Head, Corporate Communications
Agency for Science, Technology and Research
Tel: +65 6826 6281
Mobile: +65 9830 2610
Email: robin_chan@hq.a-star.edu.sg
Mr Khoo Kiak Nee
Director, Sysmatic Global
Tel : +65 6246 6859
Mobile : +65 9688 2502
Email : knkhoo@sysmaticgpl.com
About A*STAR
The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector R&D agency. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit the economy and society. As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by improving societal outcomes in healthcare, urban living, and sustainability. A*STAR plays a key role in nurturing scientific talent and leaders for the wider research community and industry. A*STAR's R&D activities span biomedical sciences to physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit www.a-star.edu.sg.
Follow us on
- Facebook: https://www.facebook.com/ASTARSG/
- LinkedIn: https://www.linkedin.com/company/astarsg/
- Instagram: https://www.instagram.com/astarsg/
- YouTube: https://www.youtube.com/astartv
- Twitter: https://twitter.com/astarsg
About Sysmatic Global
Sysmatic Global Pte Ltd was established in 2010 as an appointed agent & solution provider for Nitto Seiko, Japan, assembly products. Through the years, we had developed our own design team and evolved to a system integrator providing innovative automation solutions improving customer factory productivity and quality. Coupled with In-house Precision Machining & Sheetmetal fabrication facilities, we strive to provide a full turnkey solution to our customers. Please visit www.sysmaticgpl.com.
Topic: Research and development
Source: A*STAR
Sectors: Daily News, Healthcare & Pharm, Local Biz, MedTech
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| A*STAR |
| Dec 6, 2022 14:00 HKT/SGT |
|
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing |
| June 2, 2022 21:00 HKT/SGT |
|
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*STAR for Targeted Cancer Therapies |
| June 2, 2022 21:00 HKT/SGT |
|
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*STAR for Targeted Cancer Therapies |
| July 31, 2020 08:00 HKT/SGT |
|
Singapore Cancer Drug ETC-159 Advances Further in Clinical Trials |
| July 24, 2020 17:00 HKT/SGT |
|
MP Biomedicals and A*STAR Co-Develop Rapid Antibody Test Kit for SARS-CoV-2 |
| Oct 22, 2019 04:00 HKT/SGT |
|
Fujitsu, SMU and A*STAR Launch Digital Platform Experimentation Project using Quantum-Inspired Computing and Deep Learning Technology |
| June 28, 2019 08:00 HKT/SGT |
|
Singapore's Drug Development Efforts Given Additional Momentum with National Platforms |
| Apr 5, 2019 18:00 HKT/SGT |
|
Passing of Dr Sydney Brenner, Nobel Laureate, Renowned Pioneer in Molecular Biology, A*Star Senior Fellow |
| Jan 21, 2019 13:00 HKT/SGT |
|
Branched-Chain Amino Acids Found to Regulate the Development and Progression of Cancer |
| July 13, 2018 10:00 HKT/SGT |
|
Scientists Discover the Tuberal Nucleus' Role in Controlling Appetite and Body Weight |
| More news >> |
 |
|
|
|
